We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
MOTS-c is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most MOTS-c studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2015–2024.
Based on 13 studies · 1 meta-analysis
Confidence
ModerateBy outcome
The current evidence for MOTS-c is insufficient to assign an evidence score, based on 13 indexed studies, including 1 meta-analysis. A 16-amino-acid mitochondrial-derived peptide promoted as a metabolic regulator and 'exercise mimetic'. Honest appraisal: the evidence is almost entirely preclinical (mouse and cell studies of AMPK activation, insulin sensitivity, exercise capacity, and bone) plus human ASSOCIATION/observational studies (circulating MOTS-c vs age, metabolic status, exercise). There are essentially NO interventional human trials of administered MOTS-c — nobody has run a randomized trial giving it to people. It is not a regulated dietary supplement; injectable product is sold 'for research use only'. Representative study: PMID 39160573.
The commonly studied dose of MOTS-c is No validated human dose exists. MOTS-c has never been dose-established in a published human interventional trial. Animal studies typically use ~0.5–15 mg/kg by injection in mice/rats, which does not translate to a human regimen. Anecdotal non-clinical injectable protocols circulated online have no clinical basis, no safety validation, and must not be read as a recommendation.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Elamipretide
Mostly mechanism / observationalAn investigational mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. Honest appraisal: it is one of the most rigorously trialed mitochondrial peptides — real Phase 2/3 randomized trials exist — but its pivotal studies were largely negative. The Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy MISSED its primary endpoints, and the EMBRACE-STEMI reperfusion-injury trial failed to reduce infarct size. The clearest positive signals are in the ultra-rare Barth syndrome and in open-label / exploratory data, not in confirmatory trials. It is not an approved drug and not a dietary supplement; grey-market injectable sourcing is unstudied.
Last reviewed June 2026 · evidence from 13 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C)
A 16-amino-acid mitochondrial-derived peptide promoted as a metabolic regulator and 'exercise mimetic'. Honest appraisal: the evidence is almost entirely preclinical (mouse and cell studies of AMPK activation, insulin sensitivity, exercise capacity, and bone) plus human ASSOCIATION/observational studies (circulating MOTS-c vs age, metabolic status, exercise). There are essentially NO interventional human trials of administered MOTS-c — nobody has run a randomized trial giving it to people. It is not a regulated dietary supplement; injectable product is sold 'for research use only'.
MOTS-c has coherent mouse and cell mechanisms plus human association data, but there are zero interventional trials of administered MOTS-c in people, so it scores at the bottom of Emerging.
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — one of a small family of 'mitochondrial-derived peptides'.
It was discovered in 2015 and is framed by its discoverers as a mitochondrial signal that, under metabolic stress, translocates to the nucleus (in an AMPK-dependent way) and regulates nuclear gene expression, including antioxidant-response-element (NRF2) targets.
Mechanistically, in cells and mice it inhibits the folate–AICAR–de novo purine biosynthesis pathway, activates AMPK, and is reported to improve insulin sensitivity, increase fat oxidation, raise stress resistance, and boost physical/exercise capacity — earning the 'exercise mimetic' label.
The honest evidence picture: almost the entire functional literature is preclinical (mouse models of obesity, insulin resistance, gestational diabetes, autoimmune diabetes, osteoporosis, vascular calcification, heart failure, lung injury) plus in-vitro mechanistic work.
The human data are ASSOCIATION/observational only — circulating MOTS-c declines with age; muscle MOTS-c tracks myofiber type in healthy aging men; plasma MOTS-c responds to lipids/insulin and exercise; low circulating MOTS-c predicts adverse cardiovascular outcomes in type 2 diabetics; and a MOTS-c mtDNA polymorphism has been hypothesized to contribute to exceptional Japanese longevity.
Critically, there are NO published interventional randomized controlled trials of administered MOTS-c in humans — the metabolic and exercise 'benefits' come from rodents, and the human evidence cannot establish that injecting MOTS-c does anything in people.
MOTS-c is not an approved drug or regulated dietary supplement; injectable material is sold 'for research use only', with the attendant identity/purity/sterility risks, and long-term human effects are entirely unknown. Overall evidence is Emerging and renders as unscored: mechanistic + observational only.
In cells and mice MOTS-c activates AMP-activated protein kinase (AMPK), the cellular energy sensor, and several of its reported metabolic and bone effects are blocked by AMPK inhibition. This is a preclinical mechanism; it has not been demonstrated in humans given the peptide.
MOTS-c is reported to inhibit the folate cycle and its tethered de novo purine (AICAR) biosynthesis, which drives the AMPK activation described above. Established in cell/mouse work; an indirect proposed mechanism, not validated human pharmacology.
Under metabolic stress MOTS-c translocates to the nucleus (AMPK-dependent) and regulates nuclear genes, including antioxidant-response-element targets, interacting with the stress transcription factor NRF2 (NFE2L2). Demonstrated in cells and rodents; mechanistic only.
Endogenous MOTS-c rises in muscle and circulation with exercise, and exogenous MOTS-c is reported to enhance physical capacity and metabolic adaptation in mice, leading to the 'exercise mimetic' framing. Human data show only that exercise raises MOTS-c — not that administering MOTS-c improves human performance.
How MOTS-c works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated human dose exists. MOTS-c has never been dose-established in a published human interventional trial. Animal studies typically use ~0.5–15 mg/kg by injection in mice/rats, which does not translate to a human regimen. Anecdotal non-clinical injectable protocols circulated online have no clinical basis, no safety validation, and must not be read as a recommendation.
Can be taken without food
| Form | Type |
|---|---|
| 💊None — no form has validated human efficacy or an approved standard | Recommended |
MOTS-c is a research peptide, not an approved drug or dietary supplement. There is no quality-controlled, regulator-sanctioned product.
Minimum: 1 weeks
Optimal: 4 weeks
Cycling: Not required
Note: No evidence-based timing exists. Animal injection schedules vary; none are validated in humans.
Dose-response data unavailable. The current published research for MOTS-c does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
There are no published randomized controlled trials of administered MOTS-c in humans. Every metabolic, exercise or anti-aging benefit below comes from mouse models or cell experiments. The only human data are observational associations (circulating MOTS-c vs age, metabolic status, exercise) — they cannot show that injecting MOTS-c works in people.
In mice MOTS-c improves insulin sensitivity and prevents age- and high-fat-diet-induced insulin resistance and obesity, targeting skeletal muscle. Unproven in humans; human data are associations only.
In young, middle-aged and old mice, MOTS-c treatment enhanced physical performance and healthspan. In humans, exercise raises endogenous MOTS-c — but no trial has shown administered MOTS-c improves human exercise capacity.
In humans, circulating MOTS-c declines with age and tracks metabolic and muscle status: plasma MOTS-c responds to lipids/insulin and to fitness, and low MOTS-c predicts worse cardiovascular outcomes in type 2 diabetics. These are correlations, not evidence that supplementing MOTS-c helps.
Rodent models report MOTS-c reduces ovariectomy-induced bone loss, attenuates vascular calcification, and protects against various organ injuries, largely via AMPK and antioxidant (NRF2) signalling. Entirely preclinical.
No human safety data exist. As an injectable mitochondrial peptide with broad gene-regulatory activity, long-term and off-target effects in people are entirely uncharacterized — absence of reported harm is not evidence of safety.
Avoid — never studied in pregnancy or lactation.
Avoid or use only under medical supervision — animal data show effects on insulin sensitivity and glucose metabolism.
Avoid — MOTS-c is an unapproved, non-permitted experimental substance marketed as an 'exercise mimetic'; its status in sport is problematic.
MOTS-c improves insulin sensitivity and glucose handling in animal models. The direction and magnitude of any interaction in humans is unknown, so combining it with glucose-lowering therapy is unpredictable and warrants caution.
Tip: There is no safe verified product; risk stems from unregulated 'research use only' sourcing rather than the peptide itself.
Tip: No human safety data exist for a peptide with broad gene-regulatory activity; absence of reported harm is not evidence of safety.
Timing is flexible for MOTS-c — consistent daily use matters more than the time of day. There is no evidence-based dosing schedule because no human pharmacokinetic or efficacy trial has established one.
MOTS-c should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-related risks (infection, abscess, contamination from non-sterile product), unknown long-term / off-target effects. Use caution if any of these apply to you: Pregnancy and breastfeeding — never studied; avoid entirely; Any use expecting a regulated, quality-controlled medicine — MOTS-c is a research chemical, not an approved drug or supplement; Diabetes medication without medical supervision — MOTS-c modulates glucose/insulin pathways in animals; unpredictable additive effects in humans are unstudied.
Soy Peptides
Mostly mechanism / observationalShort, bioactive fragments enzymatically cleaved from soy protein — soy protein hydrolysates plus named peptides like lunasin and soy ACE-inhibitory peptides. Unlike whole soy protein (a complete protein with an FDA cholesterol claim) or soy isoflavones (phytoestrogens), these are specific peptide fragments studied for cholesterol, blood pressure and antioxidant effects. Honest appraisal: the evidence is mostly in-vitro and animal. The one published human RCT (lunasin) was null. Emerging, not established.